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Abstract
Viral protein U (Vpu) is a type-III integral membrane protein encoded by Human Immunode-
ficiency Virus-1 (HIV- 1). It is expressed in infected host cells and plays several roles in viral
progeny escape from infected cells, including down-regulation of CD4 receptors. But key
structure/function questions remain regarding the mechanisms by which the Vpu protein
contributes to HIV-1 pathogenesis. Here we describe expression of Vpu in bacteria, its puri-
fication and characterization. We report the successful expression of PelB-Vpu in Escheri-
chia coli using the leader peptide pectate lyase B (PelB) from Erwinia carotovora. The
protein was detergent extractable and could be isolated in a very pure form. We demon-
strate that the PelB signal peptide successfully targets Vpu to the cell membranes and
inserts it as a type I membrane protein. PelB-Vpu was biophysically characterized by circu-
lar dichroism and dynamic light scattering experiments and was shown to be an excellent
candidate for elucidating structural models.
PLOS ONE | DOI:10.1371/journal.pone.0172529 February 22, 2017 1 / 23
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Deb A, Johnson WA, Kline AP, Scott BJ,
Meador LR, Srinivas D, et al. (2017) Bacterial
expression, correct membrane targeting and
functional folding of the HIV-1 membrane protein
Vpu using a periplasmic signal peptide. PLoS ONE
12(2): e0172529. doi:10.1371/journal.
pone.0172529
Editor: Michael Schindler, University Hospital
Tuebingen, GERMANY
Received: December 14, 2016
Accepted: February 6, 2017
Published: February 22, 2017
Copyright: © 2017 Deb et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper.
Funding: This work was supported by the Center
for Membrane Proteins in Infectious Diseases
(MPID), which was funded by the PSI:Biology
program within the National Institute of General
Medical Sciences’ Protein Structure Initiative
(National Institutes of Health grant number
U54GM094599) awarded to BGH, TSM and PF.
Introduction
Structural analysis of membrane proteins has traditionally been bottlenecked by the lack of
sufficiently large amounts of pure, properly folded and functional membrane proteins. The
issue is particularly important considering the fact that membrane proteins constitute a signifi-
cant proportion of clinical drug targets.
The viral protein U (Vpu) was identified as a product of the vpu open reading frame from
the human immunodeficiency virus-1 (HIV-1) which runs as a 16 kDa protein on a SDS-
polyacrylamide gel [1]. It is a type III transmembrane protein 77–86 amino acids in length,
depending on the group and subtype of HIV-1. Vpu is not expressed by HIV-2, but is present
in some simian immunodeficiency viruses (SIVs) [2]. It has a very short N-terminal domain, a
transmembrane domain and a longer cytoplasmic domain, which has two predicted α-helical
domains, separated by a hinge region. The hinge region contains two potential casein kinase II
sites [3]. NMR characterization of the cytoplasmic domain of Vpu indicates that it exhibits a
great deal of structural flexibility [4].
Down-regulation of CD4 receptors in infected host cells is of prime importance for the
virus and it accomplishes this through the Nef and Vpu proteins. Vpu not only retains CD4 in
the endoplasmic reticulum, but also induces CD4 degradation by employing a variant pathway
of the ERAD machinery [5]. Vpu retains CD4 in the ER by virtue of interactions of the trans-
membrane domains. The conserved tryptophan residue (Trp22 in NL4-3 strain Vpu sequence)
in the transmembrane domain of Vpu plays a role in inhibiting the dislocation of the CD4
from the ER membrane to the cytosol for degradation. Val20 and Ser23 have also been identi-
fied to play a role in CD4 retention in the ER [6]. The cytosolic domain of Vpu recruits ubiqui-
tination factors, which ubiquitinate the cytoplasmic domain of CD4 at multiple lysine and
serine/threonine residues to mark CD4 for proteasomal degradation and also further contrib-
ute in retention of CD4 in the ER [5].
The transmembrane domain of Vpu is involved in its association with tetherin, leading to
the ubiquitin-dependent degradation of the latter, which in turn reduces the incorporation of
tetherin into nascent virions. According to the suggested mechanism, phosphorylated Vpu
recruits a SCG TRCP1/2 E3 ligase complex that ubiquitinates the cytoplasmic tail of tetherin at
multiple residues. A motif in the second α-helix in the cytoplasmic domain of Vpu has been
identified as responsible for efficient counteraction of tetherin [7].
Vpu has also been implicated in retention of NK, T-cell, B-cell antigen (NTB-A) in the
Golgi apparatus by altering the glycosylation pattern in nascent NTM-A. This is a part of a
strategy to prevent HIV-1-infected cells from being lysed by NK cells. This function has been
traced to the second α-helical region of Vpu in its cytoplasmic domain [8]. In addition, based
on similarities with other viral transmembrane proteins, Vpu has also been studied for possess-
ing an ion-channel activity, which could potentially make the host membrane protein more
permeable and aid in budding and release of nascent virions. Vpu has been shown to mediate
potassium transport when expressed recombinantly in Saccharomyces cerevisiae [9].
The 22-residue-long PelB signal sequence was first described in the identification and char-
acterization of Erwinia carotovora pectate lyase B gene and its protein product [10]. The
expression of the mature form of the protein in E. coli indicated that the protein translocation
machinery and signal peptidase(s) can correctly process and export the protein to the periplas-
mic space. Since then a wide variety of recombinant soluble proteins have been efficiently tar-
geted to the E. coli periplasm and also to the extracellular media using this signal peptide like
the ligand-binding domains of glutamate receptor’s B and D subunits [11], variable regions of
light and heavy chains of antibodies [12, 13], phospholipase D [14], and the C-terminal
domain of OmpC [15]. The PelB signal peptide was also used to express a pentameric ion
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channel protein ELIC with an N-terminal fusion of maltose binding protein, which led to the
successful crystallization and x-ray structure determination of ELIC [16]. It was also used to
target a fusion of the B subunit of cholera toxin and the membrane proximal region of the
gp41 protein of HIV-1, which interacts with the periplasmic side of the inner membrane in E.
coli [17–19].
In this study we report the successful expression of HIV-1 Vpu in E. coli as a type I mem-
brane protein with PelB signal sequence appended to the amino end of the protein. We also
describe the purification and characterization of the target protein towards its suitability for
structure determination by X-ray crystallography.
Results and discussion
Gene optimization, cloning and expression of PelB-Vpu
Vpu is an important accessory protein involved in HIV-1 pathogenesis. Furthermore, the pres-
ence of a transmembrane domain with an intriguing structure-function relationship makes it
an attractive target for structural studies. Previous attempts from our laboratory to express this
protein were either unsuccessful or resulted in proteins that lacked the necessary purity and
stability for crystallization. Attempts were made to express the protein using the P8CBD
expression vector described by Luo et al. [20] and also as an N-terminal fusion with the Bacillus
subtilis protein Mistic (see Kefala and Kwiatkowsk [21] and unpublished data).
In this study, unfavorable codons in the native Vpu gene from subtype B HIV-1 were
removed and replaced by codons widely used by E. coli (Fig 1). Codon optimization to increase
yield and stability of recombinant proteins has been successfully used in our laboratory for the
expression of human butyrylcholinesterase [22] and HIV-1 Gag/dgp41 virus like particles [23]
in Nicotiana benthamiana. Codon optimization of the Vpu gene has been shown to improve
its mRNA stability and magnitude of expression in HeLa cells when transcribed under the con-
trol of a CMV promoter [24].
The native vpu gene is composed of significantly unfavorable codons with respect to the E.
coli codon usage patterns, with a codon adaptation index (CAI) of 0.101. Removal of these
Fig 1. Optimization of the vpu gene for expression in E. coli. Codon usage is presented by plotting the
relative adaptiveness, w, values (a moving geometric mean with a 10-residue window) as a function of the
residue number. Codon usage analysis of the native HIV-1 Vpu gene against the reference set of E. coli and
H. sapiens are shown as red and blue traces. The codon usage of the vpu gene optimized for expression in E.
coli is shown in black. The codon adaptation index (CAI, relative adaptiveness averaged over the entire length
of a sequence) for each gene is shown as a broken line.
doi:10.1371/journal.pone.0172529.g001
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unfavorable codons and replacing them with codons more suited to the E. coli codon usage
patterns resulted in an increase of the CAI to 0.916. In the human genome, there is a weak pos-
itive correlation between frequency of optimal codons and levels of gene expression [25, 26]. It
is interesting to observe that the frequency of non-optimal codons is significantly higher for
the N-terminal part of the native protein. There is evidence to suggest that usage of low fre-
quency codons within a coding sequence could be indicative of a genetic instruction that regu-
lates the rate of protein synthesis. This phenomenon could facilitate the formation of some
secondary and/or tertiary structure in the nascent polypeptide [27, 28]. But, the idea of the
action of codon usage bias to improve translational efficiency remains unconfirmed in mam-
mals [29]. On the other hand, in unicellular organisms like E. coli, there is a strong correlation
between the most frequently used codons and the abundance of tRNAs [30, 31]. Thus, the
codon usage pattern can greatly influence the rate and efficiency of translation in E. coli [32–
34], leading to enhanced expression levels of the recombinant membrane protein. Thus, the E.
coli optimized gene was cloned into a pET26(b) expression vector to obtain pTM 875 (Fig 2)
with the addition of a C-terminal hexa-histidine tag.
Expression in E. coli
Bacterial cells harboring pTM 875 were grown to mid-logarithmic phase when 0.1 mM IPTG
was added to the culture medium to induce expression of the recombinant PelB-Vpu. At 6 h
post induction, cells were harvested and lyzed by a microfluidizer. Following cell lysis, cellular
components were fractionated into aqueous and non-aqueous fractions and their proteins
resolved by SDS-PAGE. Immunoblot analysis revealed the almost-exclusive presence of
PelB-Vpu in the water-insoluble fraction. However, PelB-Vpu could be extracted from the
water-insoluble fraction with detergents. Particularly effective in extraction of PelB-Vpu were
the maltoside detergents βDM and βDDM and the zwitterionic detergent, DPC (Fig 3). These
three detergents have relatively long and flexible hydrophobic chains, which may explain in
part the ability of these detergents to effectively extract the highly hydrophobic PelB-Vpu pro-
tein. Consistent with this possible explanation is our observation that the shorter-chained OG
and CHAPS, whose hydrophobic tail consists of a rigid steroidal ring system, have relatively
Fig 2. Organization of the expression cassette within the plasmid pTM 875. Expression was driven by a
T7 promoter as shown in (A). The Vpu gene is flanked by the PelB signal peptide at the N-terminus that
directs the protein to the periplasmic space of the bacteria and facilitates integration into the inner
membranes, and a 6x- histidine tag at the C- terminus to aid in purification. (B) shows the sequence of the
PelB signal peptide (in orange), Vpu (in green) and histidine tag (in blue). Chymotrypsin cleavage sites are
denoted by down-pointing arrows (⬇) for strong recognition sites and by an asterisk (*) for secondary sites.
doi:10.1371/journal.pone.0172529.g002
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ineffective extraction power. Long flexible hydrophobic tails may be necessary for successful
extraction of PelB-Vpu, but apparently are not sufficient as LDAO performed poorly; LDAO
solubilization power may be hampered by a very small hydrophilic head (18 Å2 as compared to
59 Å2 and 179 Å2 of DPC and the two maltoside detergents, respectively) [35–37] and a high
octanol/water partition coefficient (logP> 5.3) [37]. Future studies involving the systematic
testing of detergents with various head groups and alkyl-chain that vary by length may provide
a more conclusive explanation and may allow rational selection of the appropriate detergents
instead of the current largely empiric exercise. Based on its performance and its suitability for
downstream applications, we elected to use βDDM in all subsequent experiments.
Vpu is targeted to the membranes and inserted as a type I membrane
protein
In mammalian cells, the Vpu transmembrane domain (TMD) serves as a signal-anchor to tar-
get the protein for insertion into the membrane, but when expressed in bacteria, the TMD
does not support this insertion function, resulting in the accumulation and aggregation of the
protein in inclusion bodies [38]. The PelB leader sequence targets its cargo protein pectate
lyase B of Erwinia carotovora into the periplasm via the Sec-dependent pathway [39–41],
which is also used for targeting integral-membrane proteins to the inner membrane [42].
While PelB is commonly used to direct recombinant proteins to the periplasm of Gram-nega-
tive bacteria, there are not many examples of its application in targeting membrane proteins
to the bacterial inner membrane, as was intended here. Because the non-aqueous fraction
obtained after cell lysis contained both membranes with their respective membrane proteins
and aggregated proteins in the form of inclusion bodies, the question arose as to the partition
of the recombinant PelB-Vpu between these two compartments.
To answer this question, we have used differential extraction of PelB-Vpu from samples of
water-insoluble protein fractions obtained at various times after the beginning of recombinant
protein induction. To this end, we used our mild detergent of choice, βDDM, to extract mem-
brane proteins and subjected the residual detergent-insoluble proteins to extraction with 8 M
Urea, a chaotropic agent that can solubilize protein inclusion bodies [43–45]. Extractions were
Fig 3. Vpu fractionates with the water insoluble fraction and can be subsequently solubilized by
detergents. Whole cell lysates of E. coli BL21s expressing Vpu were fractionated into non- aqueous (lane 1)
and aqueous (lane 2) fractions by centrifugation. The non-aqueous fraction (pellets) were resuspended in
extraction buffer containing various detergents (1% final concentration): βDM (lane 3), βDDM (lane 4),
CHAPS (lane 5), OG (lane 6), LDAO (lane 7) and DPC (lane 8). Following overnight incubation at 4˚C,
detergent-soluble proteins were separated from insoluble proteins by centrifugation and fractionated by
SDS-PAGE followed by immunoblot analysis using a Vpu-specific antibody. Vpu is indicated by a black arrow.
doi:10.1371/journal.pone.0172529.g003
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carried out at the specified time points following the induction with IPTG. The amount of
PelB-Vpu extractable with βDDM increased with time during the first 6 hr post-induction (Fig
4A). However, there was no increase of the amount of PelB-Vpu that could be extracted from
homogenization pellets of cells harvested after overnight growth in the presence of IPTG as
compared to 6 hr. In striking contrast, the overnight sample had a significant increase in
amount of urea-extractable PelB-Vpu. This could be explained by saturation of the bacterial
inner membrane by 6 hr post induction and subsequent accumulation of the over-expressed
protein in intracellular inclusion bodies.
Urea cannot extract integral membrane proteins embedded in membranes, but such pro-
teins can be extracted by detergents. Conversely, detergent-extractable proteins may be present
in inclusion bodies, but such proteins should also be solubilized by urea. To rule out this sec-
ond possibility, and to further demonstrate that βDDM predominantly extracts PelB-Vpu
from the cell membranes rather than from inclusion bodies, we reversed the order of extrac-
tion such that the non-aqueous fraction was first subjected to urea extraction followed by
Fig 4. Vpu fractionates with the membrane fraction and inclusion bodies dependent on time post-
induction with IPTG. The βDDM extractable fraction increases with time until it reaches saturation around 6
hr (A). When the non-aqueous fraction is first treated with urea and then βDDM (B), the protein first
fractionates in the detergent fraction, implying that protein does integrate in the membranes that is extractable
by βDDM. Vpu is indicated by a black arrow.
doi:10.1371/journal.pone.0172529.g004
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βDDM extraction. Most of the protein from cells harvested 2 h and a comparable amount at 4
h after induction was in the βDDM extractable fraction (Fig 4B). This is consistent with results
in panel A which indicates that most of the protein localized in the membrane fraction until
around 6 h after induction with IPTG, after which the membranes may saturate and the
subsequently produced recombinant protein forms aggregates that can be solubilized by urea.
Based on this finding, the cells were harvested after 6 hr of IPTG induction for all subsequent
experiments.
The PelB sequence allows the insertion of recombinant PelB-Vpu into the membrane, how-
ever the presence of two in tandem hydrophobic domains may complicates the membrane
topology of the protein. To address this, we next sought to determine in vivo whether the pro-
tein is oriented with its N-terminus in the periplasm (functionally equivalent to the ER lumen
in human cells) and its C-terminus inside the cell (in the cytoplasm).
To this end, we treated E. coli cells expressing PelB-Vpu with lysozyme and subjected the
recovered protoplasts to mild chymotrypsin proteolysis. The C-terminal domain of Vpu con-
tains several chymotrypsin proteolytic sites, which should be protected from the protease if the
protein is inserted with its C-terminus in the cytoplasm. However, if the orientation of the pro-
tein is such that the C-terminus is externally-exposed, it will be cleaved and should not react
with the polyclonal antibodies against Vpu. Indeed, the chymotrypsin digestion assay revealed
that the C-terminal domain of Vpu is shielded from proteolytic digestion by the E. coli inner
membrane (Fig 5). In contrast, the periplasmic domain of AcrA, a native E. coli inner-mem-
brane efflux pump, was vulnerable to proteolytic cleavage. (Fig 5B). The cytoplasmic chaper-
one GroEL, like the cytoplasmic domain of Vpu, was immune to the effects of chymotrypsin
(Fig 5C and 5D respectively). Vpu and GroEL could be digested by chymotrypsin only when
the integrity of the E. coli inner membrane was compromised by treatment with the detergent
Triton X-100. Our results support the hypothesis that PelB-Vpu is inserted into the membrane
with its C-terminal domain located in the cytoplasm.
Purification of PelB-Vpu
Crude detergent extracts contain several protein bands that are recognized by the anti-VPU
antibody we used (Figs 3 and 4). Very small fragments are likely representing degradation
products, but the nature of the higher molecular mass bands is not clear. To purify PelB-Vpu
from cellular proteins and small protein fragments, we employed metal affinity chromatorgra-
phy. Immobilized metal affinity purification of membrane protein-detergent complexes can be
challenging in terms of amount and purity of the enriched protein. The choice of detergent
and buffers can have some effect on the efficiency of the purification procedure [46, 47]. The
conformation of the protein could also play a role in retention of the protein by the affinity
resin [48, 49]. The folding state can also dictate the placement of the affinity tag in the protein
and its accessibility to the metal resin [50]. Towards our effort to isolate His-tagged PelB-Vpu
from the rest of the cellular biomolecules, the βDDM solubilized fraction was subjected to
TALON metal affinity. We observe that the protein in the elution fraction was obtained in a
highly pure form (Fig 6A). We were also able to obtain PelB-Vpu protein with minimal loss
during the purification procedure in the flow-through and wash steps (Fig 6B). Although the
purity of the eluate was demonstrated by silver-stained SDS-PAGE gels, it is also important to
analyze the sample for high molecular weight aggregates, which may be undetectable due to
the denaturing and reducing nature of SDS-PAGE. With this objective, concentrated IMAC
purified protein was analyzed by size exclusion (SEC) chromatography. We observe that the
protein eluted as mostly a solitary peak. Void volume aggregates eluted as a distinctly small dis-
tinct peak before the major peak, which was easily separated and discarded (Fig 7).
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Fig 5. Vpu is inserted into the bacterial inner membrane with its C-terminal domain within the
cytoplasm. Panel A depicts the possible outcomes when E. coli cells (I) and protoplasts (II III and IV) that
express Vpu are digested with chymotrypsin alone (I-III) and in the the presence of Triton X-100 (IV). If the C-
terminal domain of Vpu is protected by the inner membrane (I and II), it is expected to be resistant to
chymotrypsin digestion, similar to the case of the cytoplasmic resident protein GroEL. If the C-terminal domain
of Vpu is exposed at the periplasmic space of the cells (III), it is expected to be digested in the same way as
AcrA. All three proteins should undergo chymotrypsin cleavage when the inner membranes are permeabilized
by the addition of Triton X-100 (IV). E. coli cells (lanes 1 and 3) and protoplasts (lanes 2 and 4–8) were
incubated without chymotrypsin (lanes 1, 2, and 7) or with the indicated concentrations of chymotrypsin (μg/
mL); in the presence of 1% Triton X-100 (lanes 7 and 8) or its absence (lanes 1–6). Following treatments, cells
were solubilized in the presence of SDS sample buffer and protein samples were resolved by SDS-PAGE
Expression of PelB-VPU
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Size of PelB-Vpu
Our results so far suggest that the fusion of the PelB signal sequence converted Vpu, a Type III
membrane protein, into a protein more akin to a Type I membrane protein. However, unlike
most Type I proteins, from which the signal peptide is typically cleaved concomitantly to their
insertion into the membrane, the apparent molecular mass of the recombinant protein of
approximately 17.5 kDa, as estimated from denaturing gels, suggests that the PelB sequence is
not cleaved off PelB-Vpu. The predicted molecular mass of Vpu based on its primary sequence
including the engineered poly-histidine tag and PelB is 12463.7 Da. If the signal peptide would
be cleaved the predicted molecular mass would be is 10,064.7 Da. However, Vpu is known to
migrate with apparent MW of ~16 kDa when analyzed by SDS-PAGE [1].
Interestingly, a band appears below the full-length PelB-Vpu (~15 kDa). Following metal-
affinity chromatography, we could detect the presence of the lower MW band by immunoblot-
ting but not by silver-staining. The fact the band co-purifies with the full-length PelB-Vpu
suggests that the former retains its C-terminal His tag. It is therefore possible that the protein
followed by immunoblotting with antibodies against the periplasmic domain of the inner-membrane protein
AcrA (Panel B, red arrow), cytoplasmic protein GroEL (Panel C, blue arrow) or Vpu C-terminal domain (Panel
D, black arrow).
doi:10.1371/journal.pone.0172529.g005
Fig 6. Protein analysis of the talon metal affinity chromatography purification of PelB-Vpu. Protein
fractions were subjected to SDS-PAGE followed by silver staining (A) and immunoblotting (B). Detergent
(βDDM)-soluble fraction containing PelB-Vpu (lane 1) was loaded onto a column containing Talon resin that
was pre-equilibrated with 20 mM HEPES, pH 7.5, supplemented with 500 mM NaCl, 5 mM imidazole, and
0.02% βDDM. Unbound proteins in the flow through were collected (lane 2) and the column was washed
consecutively with four different buffer solutions (20 mM HEPES, pH 7.5): W1 (lane 3, buffer plus 500 mM
NaCl), W2 (lane 4, buffer plus 500 mM NaCl and 0.02% βDDM), W3 (lane 5, buffer plus 250 mM NaCl and
0.02% βDDM), and W4 (lane 6, buffer plus 250 mM NaCl, 0.02% βDDM and 10 mM imidazole). Pure
PelB-Vpu was eluted with W4 buffer supplemented with 300 mM imidazole (lane 7, arrows).
doi:10.1371/journal.pone.0172529.g006
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represents a small population of Vpu protein obtained upon cleavage of the PelB leader
sequence.
To more accurately determine the size of bacterially-produced PelB-Vpu, we subjected the
SEC-FPLC-purified protein to mass spectrometry (MALDI-TOF, Fig 8). The peak represent-
ing the MH+ form of the protein at 12467.7 Da, corresponds well to the scenario in which the
PelB signal peptide remains uncleaved. Inefficient cleavage by periplasmic peptidases could be
a result of steric hindrance due to the proximity of the cleavage site and the five residue-long
N-terminal ectodomain to the hydrophilic heads of phospholipids in the outer leaflet the
plasma membranes of E. coli. Note that the mass spectrogram does not indicate the presence of
the lower molecular mass Vpu, which was likely removed at the SEC-FPLC stage.
Fig 7. Size-exclusion chromatography of concentrated metal-affinity chromatography-purified
PelB-VPU. Eluate from Fig 6 was subjected to SEC-FPLC. Sec resin: Superdex 200 10/300 GL; Flow-rate:
0.5 mL/min, Running buffer: 20 mM HEPES, pH 7.5, 250 mM NaCl, 5% glycerol and 0.02% βDDM. The minor
peak at 8 mL corresponded to the void volume, and the major peak at 11.48 mL contained PelB-Vpu. The
column was calibrated with cytochrome c (A), carbonic anhydrase (B), albumin (C), alcohol dehydrogenase
(D), β-amylase (E) and blue dextran (F) and a standard curve was obtained as shown in the inset. The size of
the Pel-B-Vpu- βDDM complex was estimated to be 315 kDa.
doi:10.1371/journal.pone.0172529.g007
Fig 8. MALDI-TOF spectrum of PelB-Vpu reveals that the purified protein retains the PelB peptide. The
major peak corresponding to the MH+ form of the protein was detected at 12467.7 Da.
doi:10.1371/journal.pone.0172529.g008
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The accurate determination of the oligomeric state of a membrane protein in a protein-
detergent micelle complex is very difficult. The size of the non-denatured PelB-Vpu within the
context of its associated βDDM micelle is shown by size exclusion chromatography to be
around 315 kDa (Fig 7). This indicates that PelB-Vpu exists as an oligomer in complex with
the βDDM micelles. The size of empty βDDM micelles size is estimated to be 60–70 kDa [51–
54], however, it is difficult to predict the size of the βDDM-protein micelles as the detergent
micelle “belt” surrounding a membrane protein is larger than an empty micelle.
Preparations of purified PelB-Vpu are uniform and the protein is folded
and stable
Dynamic light scattering of purified PelB-Vpu preparations reveals very low dispersity at a
concentration of 5 mg/mL and 10 mg/mL with a 10.4±0.1 nm hydrodynamic radius (data
not shown and Fig 9). This estimation was fairly consistent upon re-runs of the experiment
as is evident by the histogram depicting the frequency of each size estimation over 10 runs
(Fig 9B). The hydrodynamic radius corresponds to a protein-detergent complex of about
332.2 kDa, corresponding well to the molecular mass estimates reported above for size-exclu-
sion chromatography.
Circular dichroism (CD) was used to estimate the secondary structure of PelB-Vpu. The
CD spectrum of PelB-Vpu displayed two negative peaks at 208 and 222 nm, characteristic of a
α-helical protein. Spectra for wavelengths below 200 nm could not be obtained because of
interference from the chloride ions in the buffer. Analysis of the PelB-Vpu CD data (in 20 mM
HEPES pH 7.5, 250 mM NaCl, 0.02% βDDM, and 5% glycerol) by CONTINLL in the CDPro
software package indicated 55.6% right handed helix, 23% left handed helix, 3.3% sheets, 2%
turns and 16% random elements, corresponding well to in silico analysis with the secondary
structure prediction tool, GOR [55], which estimated 65.2% helices in the sequence.
Purified PelB-Vpu was observed to be stable up to around 40˚C after which a temperature-
dependent disintegration of the α-helical secondary structure was observed (Fig 10A). It was
also observed that the protein was stable across a wide range of salt concentrations (Fig 10B).
Purified PelB-Vpu can selectively associate with CD4
The interaction with CD4 and its subsequent degradation is one of the well-characterized
functions of Vpu. This interaction has been shown to be dependent on a combination of spe-
cific amino acids and structural features in the transmembrane and cytoplasmic domains of
both proteins. Scrambling the amino acids of the transmembrane domain of Vpu, while pre-
serving its hydrophobicity, decreased its ability to down-regulate surface expression of CD4 in
HeLa CD4+ cells [56]. This indicates that interactions between the two proteins were dis-
rupted. It has also been shown that specific amino acids in the cytoplasmic domain of CD4
[57] and Vpu are required for their interaction [58]. Furthermore, it was also demonstrated
that the formation of α-helical structures in the cytoplasmic domains of both Vpu and CD4
are critical for CD4-Vpu interactions [59]. The transmembrane and cytoplasmic domains of
CD4 were expressed as an N-terminal fusion with maltose binding protein (MBP) in BL21
(DE3) E. coli cells. To determine if PelB-Vpu interacts with CD4, the fusion protein in βDDM
micelles was purified by metal affinity chromatography and size exclusion chromatography.
PelB-Vpu in βDDM micelles was pulled down only when the protein was incubated with the
CD4 TMD/cytoplasmic domain-MBP fusion protein (Fig 11A and 11B, lanes 5). This indicates
that PelB tag does not abolish interaction between the two proteins as measured by our pull-
down assay.
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Conclusions
The requirement to produce substantial quantities of pure, folded, functional and monodis-
persed protein is a a major factor that hampers elucidation of membrane protein structural
models. We demonstrate successful expression of good quantities of HIV-1 Vpu when
expressed with the PelB signal sequence appended to the amino end of the protein. The signal
peptide was not cleaved from the majority of the protein. The fusion protein was folded, mono-
dispersed and a pull-down assay indicates that the protein retains its ability to interact with the
TMD and cytoplasmic tail of CD4 which has been shown to be functionally important for
interaction and retention of the protein in cells. We hypothesize that efficient cleavage of the
signal peptide was inhibited by the inability of the periplasmic peptidases to access the cleavage
Fig 9. Dynamic light scattering measurements show that PelB-Vpu is monodispersed. The complex of
detergent and PelB-Vpu was detected as a narrow peak at 10 nm. A molecular weight of 332.2 kDa was
predicted for the protein-detergent complex. Monodispersity of PelB-Vpu (10 mg/mL) is shown by the heat
map diagram (A) and a plot of frequency of each particle size estimated from multiple measurements (B).
doi:10.1371/journal.pone.0172529.g009
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site. Nevertheless, this expression strategy can serve as the basis for further Vpu structural stud-
ies and possibly a template that will be applicable for other membrane proteins as well.
Materials and methods
Target selection, gene optimization and cloning
The sequence of HIV- 1 group M subtype B strain HXB2 Vpu was used. Unfavorable codons
for each 82 amino acids in length were replaced using the E. coli codon usage table [60].
Codon usage bias analysis was based on a set of genes encoding highly expressed proteins of E.
coli according to Sharp and Li [61] and based on the E. coli codon usage table (ibid). The equiv-
alent set of human cDNAs is described in Table 1. Using Sharp and Li’s methodology [61], we
calculated the values of the following parameters: relative synonymous codon usage (RSCU,
defined as observed frequency/expected unbiased frequency), the relative codon adaptiveness
(w, RSCU normalized to the most abundant synonymous codon for each amino acid) and the
codon adaptation index (CAI, geometric mean of w values over the entire length of the gene).
Codons with w<0.5 are considered “unfavorable” (i.e. infrequently used).
Fig 10. Circular dichroism spectrometry analysis shows that PelB-Vpu is stable (A) at various
temperatures up to 40˚C and (B) across a wide spectrum of salt concentrations.
doi:10.1371/journal.pone.0172529.g010
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The vpu gene optimized for expression in E. coli was synthesized by overlap extension PCR.
Overlapping oligonucleotides, oTMs 638–645 (Table 2) of sizes ranging from 30–40 bases
were ordered from Integrated DNA Technologies. The first round of PCR (Roche High Fidel-
ity PCR Kit; cat# 11732641001) to assemble to the gene was done for 25 cycles (initial denatur-
ation: 94˚C for 2 min; denaturation: 94˚C for 15 s; annealing: 55˚C for 30 s; elongation 72˚C
for 30 s; final elongation: 72˚C for 7 min) and was followed by a second round of PCR with
external primers oTMs 646 and 647 for 40 cycles for amplification (initial denaturation: 94˚C
for 2 min; denaturation: 94˚C for 15 s; annealing: 58˚C for 30 s; elongation 72˚C for 30 s; final
elongation: 72˚C for 7 min). The PCR product was first cloned into a TOPO-TA intermediate
cloning vector (Invitrogen; cat# 450641). The vpu gene was sub-cloned into a TOPO-TA vec-
tor with flanking NcoI and BlpI sites and a C-terminus hexa-histidine tag using oTMs 787 and
788 and was excised from this intermediate vector by digestion with NcoI (NEB; cat# R3193S)
and BlpI restriction enzymes (NEB; cat# R0585S). The same pair of restriction enzymes were
also used to linearize the pET26(b) vector by Novagen. The restriction digestion reactions
were analyzed by agarose gel electrophoresis and the desired DNA bands were excised and
purified using a QIAquick gel extraction kit (Qiagen; cat# 28704). The gene was ligated to the
pET26(b) vector by performing a T4 DNA ligase reaction (Promega; cat# M1801) and trans-
formed into DH5α electro-competent cells. The resulting bacterial colonies were screened
using colony screen PCR using gene specific primers oTMs 662 and 663 and plasmid specific
primers, oTMs 856 and 857. DNA sequencing using oTMs 856 and 857 was used to verify the
final expression clone, pTM 875.
Expression
The expression of PelB-Vpu with the N-terminal PelB signal peptide, along with the C-termi-
nal hexa-histidine affinity tag was driven by a T7 promoter. E. coli BL21 DE cells were trans-
formed with the expression vector, pTM 875 by electroporation. For protein expression, an
overnight culture of BL21 DE cells containing the expression vector was grown in LB media
supplemented with 100 μg/mL kanamycin (Phytotechnology lab; cat# K378) and was used to
inoculate a fresh LB media with 50 μg/mL kanamycin in a 1:100 dilution. The cultures for
expression were shaken at 200 rpm at 37˚C to mid-logarithmic phase (OD600 0.4). The
Fig 11. Co-immunoprecipitation of PelB-Vpu with CD4. Purified CD4 TMD + cytoplasmic domain fused to
the amino end of MBP (CD4-MBP) was incubated with PelB-Vpu in βDDM micelles. The complex was
captured by anti- MBP antibody-conjugated beads and pelleted by centrifugation and analyzed by SDS-PAGE
followed by Coomassie staining (A) and immunoblot analysis with Vpu antibodies (B). Panel A depicts all
proteins pulled down by only agarose beads (lane 1) and agarose beads conjugated with anti-MBP (lanes
2–5). Anti-MBP, CD4-MBP, MBP and Vpu are denoted by blue, green, red and black arrows respectively.
Beads were incubated with purified proteins: CD4-MBP (lane 1), MBP and Vpu (lane 2), CD4-MBP (lane 3),
Vpu lane 4), CD4-MBP and Vpu (lane 5).
doi:10.1371/journal.pone.0172529.g011
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cultures were then moved to 15˚C and incubated for additional 30 min with 200 rpm shaking.
Finally the cultures were induced for expression with 0.1 mM Isopropyl-β-D-thiogalactoside
(IPTG, Roche; cat# 11411446001). For standardization of expression conditions, 5 mL of cul-
ture were collected at various time points after IPTG induction and pelleted by centrifugation
at 5000 ×g, 4˚C for 15 min. For detergent extraction screens and subsequent purifications, cells
Table 1. Highly-expressed human gene set used in codon usage optimization.
Gene Description Accession Number
dclre1A DNA cross-link repair 1A NM_014881
dnaJ Heat shock protein, Hsp40 NM_173650
eef1D Homo sapiens eukaryotic translation elongation factor 1 delta NM_001130055
eef1G H. sapiens eukaryotic translation elongation factor 1 gamma NM_001404
eif2B3 H. sapiens eukaryotic translation initiation factor 2B subunit gamma NM_001166588
eif4E2 H. sapiens eukaryotic translation initiation factor 4E NM_004846
eif4ebp1 H. sapiens eukaryotic translation initiation factor 4E binding protein 1 NM_004095
old35 H. sapiens 3’-5’ RNA exonuclease AY027528
psmc1 H. sapiens proteasome 26S subunit, ATPase 1 NM_002802
psmd7 H. sapiens proteasome 26S subunit non-ATPase, 7 NM_002811
rpl5 H. sapiens ribosomal protein L5 NM_000969
rpl10 H. sapiens ribosomal protein L10 NG_012890
rpl11 H. sapiens ribosomal protein L11 NM_000975
rpl12 H. sapiens ribosomal protein L12 NM_000976
rpl18 H. sapiens ribosomal protein L18 NM_000979
rpl19 H. sapiens ribosomal protein L19 NM_000981
rpl22 H. sapiens ribosomal protein L22 NM_000983
rpl23 H. sapiens ribosomal protein L23 NM_000978
rpl26 H. sapiens ribosomal protein L26 NM_000987
rpl27A H. sapiens ribosomal protein L27A NM_000990
rpl30 H. sapiens ribosomal protein L30 NM_000989
rpl32 H. sapiens ribosomal protein L32 NM_000994
rpl34 H. sapiens ribosomal protein L34 NM_033625
rpl35A H. sapiens ribosomal protein L35A NG_011743
rpl36A H. sapiens ribosomal protein L36A NG_012523
rpl39 H. sapiens ribosomal protein L39 NG_016250
rplP0 H. sapiens ribosomal protein lateral stalk subunit P0 NM_001002
rplP1 H. sapiens ribosomal protein lateral stalk subunit P1 NM_001003
rps2 H. sapiens ribosomal protein S2 NM_002952
rps4X H. sapiens ribosomal protein S4, X-linked NG_012524
rps6kA4 H. sapiens ribosomal protein S6 kinase A4 NM_003942
rps6kC1 H. sapiens ribosomal protein S6 kinase C1 NM_001136138
rps11 H. sapiens ribosomal protein S11 NM_001015
rps12 H. sapiens ribosomal protein S12 NM_001016
rps15 H. sapiens ribosomal protein S15 NM_001018
rps17 H. sapiens ribosomal protein S17 NM_001021
rps19 H. sapiens ribosomal protein S19 NG_007080
rps20 H. sapiens ribosomal protein S20 NM_001023
rps23 H. sapiens ribosomal protein S23 NM_001025
rps24 H. sapiens ribosomal protein S24 NM_001142284
rpsA H. sapiens ribosomal protein SA NM_002295
doi:10.1371/journal.pone.0172529.t001
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were harvested at 6 h post induction by centrifugation at 5000 ×g, 4˚C for 15 min. Cell pellets
were stored at -80˚C until further use.
Separation of water-soluble and insoluble fractions
Cell pellets from 4 L worth of culture (approximately 12 g) were re-suspended in 100 mL of
ice-cold PBS-PI buffer (phosphate buffer saline, PBS, supplemented with EDTA-Free SIGMA-
FAST™ Protease Inhibitor Cocktail tablets, Sigma; cat# S8830). The cells were lysed by double
passage through a microfluidizer (Microfluidics Microfluidizer). The lysate was collected and
centrifuged at 36,000 ×g for 30 min at 4˚C. The insoluble fraction, containing the inner and
outer membranes among other insoluble materials like protein inclusion bodies, was washed
once by repeated re-suspension (50 mL of ice-cold PBS with protease inhibitor cocktail) and
centrifugation. The pellet was frozen at -80˚C until further use.
Detergent extraction
Aqueous and non-aqueous fractions from 500 mL cultures were prepared as described above.
induced for expression and cells were harvested as pellets as mentioned previously. The pellet
containing the non-aqueous proteins was re-suspended in 25 mL of PBS-PI buffer. Samples (4
mL) were then subjected to detergent extraction by addition of the following detergents to
final concentration of 1% (w/v): n-dodecyl-β-D-maltoside (βDDM, Glycon Biotech; cat#
D97002C), n-decyl-β-D-maltoside (βDM, Anatrace; cat# D322), 3-[(3-Cholamidopropyl)
dimethylammonio]-1-propanesulfonate (CHAPS, Mclab; cat# DCPS101), n-octyl β-D-gluco-
pyranoside (OG, Glycon Biotech; cat# D97001C), n-dodecylphosphocholine (DPC, Anatrace;
cat# F308S) and n-dodecyl-N,N-dimethylamine-N-oxide (LDAO, Anatrace; cat# D360). The
samples were left overnight at 4˚C with agitation at 200 rpm and centrifuged at 36,000 ×g for
30 min at 4˚C on the following day and the supernatant was collected as the detergent soluble
fraction. The fractions were analyzed by SDS-PAGE followed by Coomassie staining and west-
ern blot.
Table 2. Oligonucleotide used in this work.
Primer Sequence (5’ to 3’)
oTM 638 ggtaccatgcagccgatcccgatcgttgctatcgtagcactggttgtagctatcatc
oTM 639 atgataacgatggaccatacaacgattgcgatgatgatagctacaaccagtgctacgatagcaac
oTM 640 atcgcaatcgttgtatggtccatcgttatcatcgaataccgtaaaatcctgcgtcagcgtaaa
oTM 641 cgatcagacgatcgatcagacggtcgattttacgctgacgcaggattttacggtattcg
oTM 642 atcgaccgtctgatcgatcgtctgatcgaacgtgcagaagactctggcaacgaatc
oTM 643 catttcaaccagtgcagagatttcaccttcggattcgttgccagagtcttctgcacgtt
oTM 644 cgaaggtgaaatctctgcactggttgaaatgggtgttgaaatgggtcaccacgctcc
oTM 645 gtcgaccagatcgtcaacgtcccacggagcgtggtgacccatttcaacacc
oTM 646 ggtaccatgcagccgatcccg
oTM 647 gtcgaccagatcgtcaacgtccc
oTM 662 atgcagccgatcccgatcg
oTM 663 cagatcgtcaacgtcccacgg
oTM 787 ccatgggcatgcagccgatcccgatcgttgc
oTM 788 gctcagcttaatggtgatggtgatggtg cagatcgtcaacgtcccacggagcg
oTM 856 atgaaatacctgctgccgaccgctgc
oTM 857 cccattcgccaatccggatatagttcctcc
doi:10.1371/journal.pone.0172529.t002
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For large-scale extractions from 4 L cultures, the pellet, containing the membrane fraction,
was fully re-suspended in 200 mL PBS supplemented with EDTA-Free SIGMAFAST™ Protease
Inhibitor Cocktail tablets. βDDM was used for solubilization at a final concentration of 1%
(w/v). The protein was extracted and at 4˚C overnight with agitation at 200 rpm. The detergent
soluble fraction was obtained by collecting the supernatant after centrifugation at 36,000 ×g
for 30 min at 4˚C.
Purification
A gravity driven column (Bio-Rad Econo-column) containing 60 mL bed volume of TALON
metal affinity resin (Clontech laboratories Ltd; Cat# 635503) was equilibrated with binding
buffer (20 mM HEPES pH 7.5, 500 mM NaCl, 0.02% βDDM, 5 mM imidazole). The sample
was then loaded onto the column, and passed twice. The column was washed with ten bed vol-
umes of wash buffers containing various combinations of salt and imidazole, for example, 20
mM HEPES, pH 7.5 with 500 mM NaCl (Wash I), 500 mM NaCl, 0.02% βDDM (Wash II),
250 mM NaCl, 0.02% βDDM (Wash III) and 250 mM NaCl, 0.02% βDDM, 5% glycerol, 10
mM imidazole (Wash IV) to remove weakly bound proteins. Tightly bound proteins were
eluted by application of 3 bed volumes of elution buffer (20mM HEPES pH 7.5, 250 mM NaCl,
0.02% βDDM, 5% glycerol, 300 mM imidazole).
The eluted sample was concentrated by 100 kDa molecular weight cutoff (MWCO) concen-
trators (Millipore; cat# UFC910024) to approximately 20 times its original volume. Concen-
trated samples were further purified by size exclusion chromatography (GE Life sciences,
Superdex 200 10/300 GL; column volume: 24 mL; fluid phase: 8 mL) using a fast pressure liq-
uid chromatography instrument (FPLC, Pharmacia, A¨kta Explorer). The running buffer con-
tained 20 mM HEPES pH 7.5, 250 mM NaCl, 0.02% βDDM, and 5% glycerol. For preparatory
separations, a 1 mL sample of concentrated PelB-Vpu was loaded onto the SEC column and
chromatography was performed at a flow rate of 0.5 mL/min. The protein elution was detected
by absorption at 280 nm. The concentration of protein in the desired peak was determined
spectrophotometrically (A280) based on the primary sequence of PelB-Vpu; S280 was calculated
with ProtParam web application (http://web.expasy.org/protparam/).
Determination of PelB-Vpu orientation in the E. coli inner membranes
A 500 mL LB media, supplemented with 50 μg/mL kanamycin, was inoculated with an over-
night culture of BL21 –pTM 875 at a dilution of 1:100. The culture was grown and induced
with 0.1 mM IPTG as mentioned above. The culture was allowed to shake at 180 RPM for 3 hr
at 15˚C post-induction after which the cells were harvested by centrifugation at 5000 ×g for 15
min at 4˚C. The cells were gently and thoroughly re-suspended in 10 mL of 200 mM TRIS, 500
mM sucrose and 0.1 mM EDTA and were distributed into 1 mL aliquots. Lysozyme was added
at a final concentration of 2 mg/mL and mixed 3 times with gentle inversion and incubated on
ice for 20 min. Calcium chloride was added at a final concentration of 30 mM and chymotryp-
sin at 1:1000, 1:100 and 1:50 v/v ratio was added to the appropriate tubes from a stock of 1 mg/
mL. Triton X-100 was added at a final concentration of 2% for controls performed with fully
lysed cells. The digestion was done at 25˚C for 1 hr, with gentle mixing every 15 min. Finally,
the cells were lysed by the addition of SDS sample buffer and heating at 100˚C before analyzing
the results by SDS gel electrophoresis followed by immunoblot and coomassie staining.
Co-immunoprecipitation with CD4
A deconstructed version of human CD4 containing the transmembrane and the cytoplasmic
domains with an N-terminal fusion of maltose binding protein was expressed in BL21 cells.
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The protein was extracted and solubilized in buffer containing 0.02% βDDM and purified by
metal affinity followed by size exclusion chromatography. MBP was expressed with an N-
terminal histidine tag in BL21 strain of E. coli cells and similarly purified by metal affinity
and size exclusion chromatography. 25 μM of the MBP-CD4 fusion was incubated with
50 μM PelB-Vpu for 45 min at 4˚C. The reaction was incubated with antibodies against
MBP at a dilution of 1:200 for 1 hr followed by 20 μL of Protein A/G PLUS- Agarose immu-
noprecipitation reagent (Santa Cruz Biotechnology; cat # sc-2003) overnight at 4˚C. The
agarose beads were pelleted by centrifugation at 500 ×g for 5 min at 4˚C. The beads were
washed 4 times with 1 mL of 20 mM HEPES pH 7.5, 250 mM NaCl, 0.02% βDDM and cen-
trifuged for 500 ×g for 5 min at 4˚C. Finally, the beads were resuspended in 1x SDS sample
buffer and were analyzed by SDS-PAGE followed by immuno-blot analysis using antibodies
against Vpu.
Gel electrophoresis, staining and western blots
SDS-PAGE using TRIS—based buffers (25 mM TRIS, 200 mM glycine and 3.5 mM SDS) was
performed in a Bio-Rad Mini-PROTEAN Tetra Cell. Following electrophoresis, gels were
stained by Coomassie brilliant blue, subjected to silver staining, or processed for immuno-
blotting. For immuno-blotting, the acrylamide gel was first rinsed with water and equilibrated
in a non-denaturing buffer (25 mM TRIS base and 200 mM glycine). The nitrocellulose mem-
brane (Bio-Rad; cat# 162–0112) was also equilibrated in the non-denaturing buffer. The gel
and the membrane were sandwiched between extra-thick blot filter papers (VWR; cat# 28298–
014) soaked in the non-denaturing buffer and proteins were electro- blotted for 15 min at 15 V
using a Bio-Rad Transfer-blot SD Semi-dry Transfer Cell. Following an hr long blocking in
PBSTM (PBS, 0.05% Tween 20 and 5% dry milk), the nitrocellulose membrane was further
incubated in the presence of the appropriate primary antibody. The membrane was then
washed 3×15 min in PBST (PBS and 0.05% Tween 20) prior to a 1 hr incubation with the
appropriate secondary antibody conjugated to horseradish peroxidase. Following additional
3x 15 min washes, the nitrocellulose membrane was then soaked in Immunocruz western blot-
ting luminol reagent (Santa Cruz Biotechnology; cat# sc-2048), exposed to a chemilumines-
cence sensitive film (GE Heathcare; cat# 28906838) for the optimum time of exposure and the
film was developed with a Konica SRX-101A system. Anti- Vpu polyclonal antibody, raised in
rabbits, was kindly provided by the NIH’s AIDS Reagent Program and was used at a dilution
of 1:30,000. Antibodies against AcrA and GroEL were raised in rabbits. Goat anti-rabbit IgG—
HRP (Santa Cruz Biotechnology; cat# sc-2923) and rabbit anti-mouse IgG-HRP (Sigma A-
9044) were used at a dilution of 1:10,000 in PBSTM.
Mass spectrometry
We used matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) Mass spec-
trometry (MS) to accurately measure the molecular weight of the purified PelB-Vpu protein.
Purified PelB-Vpu (1 μL of 10 mg/mL) was added to 4 μl of sinapinic acid matrix solution
(67:33 water:acetonitrile (v/v) containing 0.4% trifluoroacetic acid in the total volume, satu-
rated with sinapinic acid). The protein/ matrix mixture (1 μL) was added onto a steel target
plate and allowed to dry in air. An external calibration spot prepared in a similar manner was
placed near the PelB-Vpu protein spot. The plate was then placed into a Bruker microflex
MALDI-TOF mass spectrometer, and spectra were collected in a positive linear mode over a
mass range from 1 to 30 kDa. The final results represented the average of 10 separate spectra.
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Circular dichroism
A JASCO J-710 CD spectro-polarimeter was used for measuring the Circular dichroism (CD)
spectra of the purified sample at various salt and temperature conditions. The SEC-purified
PelB-Vpu (eluted in 20 mM HEPES pH 7.5, 250 mM NaCl, 0.02% βDDM, and 5% glycerol)
was concentrated to 10 mg/mL by a 100-kDa concentrator and CD measurement was done on
samples containing a final protein concentration of 0.5 mg/mL. A baseline CD spectrum
was obtained for the buffer and these values were subtracted from the CD measurement of
PelB-Vpu. CD spectra for the protein were recorded from 190 to 260 nm using a 0.1 cm quartz
cuvette. To obtain readings for the protein at different salt concentrations, a temperature of
20˚C was maintained throughout. Parameters were set at 1 nm data pitch, continuous scan-
ning mode, a scanning speed of 50 nm/min, a response of 4 s, and a spectral bandwidth of 1
nm. Output spectra were generated based on an accumulation of five scans. The molar elliptic-
ity (θ) in deg.cm2/dmol was calculated as described by [62].
Dynamic light scattering
Dynamic light-scattering (DLS) measurements were performed using a NaBiTec GmbH setup
comprising a SpectroSize 302 (Molecular Dimensions) in combination with an S6D micro-
scope (Leica). The purified protein sample was concentrated to 10 mg/mL as described earlier
was illuminated in a 2 μl hanging drop using a 24-well crystallization plate (VDX Greased
Plate, Hampton Research) covered with siliconized-glass circular cover slides (22 mm; Hamp-
ton Research). The well itself was filled with 400 μl SEC running buffer. Prior to the measure-
ment, the protein solution was centrifuged at 18000 ×g, 30 min, 4˚C to remove possible dust
and other suspended particles. All measurements were done at 20˚C. Ten consecutive mea-
surements, each with an integration time of 20 s, were averaged. Hydrodynamic size of the par-
ticles was estimated with the instrument software using the following parameters: refractive
index 1.33, viscosity 1.006, shape factor 1.0 and hydrated shell 0.2 nm.
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